These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 28560458

  • 1. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
    Cuyàs E, Queralt B, Martin-Castillo B, Bosch-Barrera J, Menendez JA.
    Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
    [Abstract] [Full Text] [Related]

  • 2. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, Menendez JA.
    Oncotarget; 2016 Dec 13; 7(50):82185-82199. PubMed ID: 27636997
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G, Cardone C, Vitiello PP, Belli V, Napolitano S, Troiani T, Ciardiello D, Della Corte CM, Morgillo F, Matrone N, Sforza V, Papaccio G, Desiderio V, Paul MC, Moreno-Viedma V, Normanno N, Rachiglio AM, Tirino V, Maiello E, Latiano TP, Rizzi D, Signoriello G, Sibilia M, Ciardiello F, Martinelli E.
    Mol Cancer Ther; 2019 Apr 13; 18(4):845-855. PubMed ID: 30824612
    [Abstract] [Full Text] [Related]

  • 5. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A.
    Int J Cancer; 2015 Jan 01; 136(1):83-90. PubMed ID: 24806288
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.
    Cercek A, Braghiroli MI, Chou JF, Hechtman JF, Kemeny N, Saltz L, Capanu M, Yaeger R.
    Clin Cancer Res; 2017 Aug 15; 23(16):4753-4760. PubMed ID: 28446505
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C.
    Oncology; 2014 Aug 15; 87(1):7-20. PubMed ID: 24968756
    [Abstract] [Full Text] [Related]

  • 9. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F.
    J Clin Oncol; 2015 Mar 01; 33(7):692-700. PubMed ID: 25605843
    [Abstract] [Full Text] [Related]

  • 10. The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.
    Youngblood VM, Kim LC, Edwards DN, Hwang Y, Santapuram PR, Stirdivant SM, Lu P, Ye F, Brantley-Sieders DM, Chen J.
    Cancer Res; 2016 Apr 01; 76(7):1825-36. PubMed ID: 26833123
    [Abstract] [Full Text] [Related]

  • 11. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
    Sukka-Ganesh B, Mohammed KA, Kaye F, Goldberg EP, Nasreen N.
    BMC Cancer; 2012 Jul 23; 12():309. PubMed ID: 22824143
    [Abstract] [Full Text] [Related]

  • 12. EphA2 receptor activation by monomeric Ephrin-A1 on supported membranes.
    Xu Q, Lin WC, Petit RS, Groves JT.
    Biophys J; 2011 Dec 07; 101(11):2731-9. PubMed ID: 22261062
    [Abstract] [Full Text] [Related]

  • 13. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.
    Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R.
    Cancer Treat Rev; 2015 Sep 07; 41(8):653-9. PubMed ID: 26220150
    [Abstract] [Full Text] [Related]

  • 14. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y, Guo M, Wei Y, Yu S, Li H, Wang Y, Xu X, Cui Y, Tian J, Liang L, Peng K, Liu T.
    Oncotarget; 2016 Dec 06; 7(49):80888-80900. PubMed ID: 27825133
    [Abstract] [Full Text] [Related]

  • 15. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
    Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M.
    Oncotarget; 2017 May 23; 8(21):35289-35300. PubMed ID: 27852040
    [Abstract] [Full Text] [Related]

  • 16. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
    Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W.
    J Biol Chem; 2013 Jun 21; 288(25):18448-57. PubMed ID: 23661698
    [Abstract] [Full Text] [Related]

  • 17. Ligand targeting of EphA2 enhances keratinocyte adhesion and differentiation via desmoglein 1.
    Lin S, Gordon K, Kaplan N, Getsios S.
    Mol Biol Cell; 2010 Nov 15; 21(22):3902-14. PubMed ID: 20861311
    [Abstract] [Full Text] [Related]

  • 18. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
    Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE.
    Biochem Biophys Res Commun; 2004 Aug 06; 320(4):1096-102. PubMed ID: 15249202
    [Abstract] [Full Text] [Related]

  • 19. A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer.
    Georgiou A, Stewart A, Vlachogiannis G, Pickard L, Valeri N, Cunningham D, Whittaker SR, Banerji U.
    Cell Oncol (Dordr); 2021 Oct 06; 44(5):1197-1206. PubMed ID: 34462871
    [Abstract] [Full Text] [Related]

  • 20. Roles of EphA1/A2 and ephrin-A1 in cancer.
    Ieguchi K, Maru Y.
    Cancer Sci; 2019 Mar 06; 110(3):841-848. PubMed ID: 30657619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.